Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐ PD ‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients
Head & Neck · 2025
DOI: 10.1002/hed.27878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Dan P Zandberg und 12 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH/NCI SPORE in Head and Neck Cancer, NCI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Background
We retrospectively evaluated radiomics as a predictor of the tumor microenvironment (TME) and efficacy with anti‐PD‐1 mAb (IO) in R/M HNSCC.
Methods
Radiomic feature extraction was performed on pre‐treatment CT scans segmented using 3D slicer v4.10.2 and key features were selected using LASSO regularization method to build classification models with XGBoost algorithm by incorporating cross‐validation techniques to calculate accuracy, sensitivity, and specificity. Outcome measures evaluated were disease control rate (DCR) by RECIST 1.1, PFS, and OS and hypoxia and CD8 T cells in the TME.
Results
Radiomics features predicted DCR with accuracy, sensitivity, and specificity of 76%, 73%, and 83%, for OS 77%, 86%, 70%, PFS 82%, 75%, 89%, and in the TME, for high hypoxia 80%, 88%, and 72% and high CD8 T cells 91%, 83%, and 100%, respectively.
Conclusion
Radiomics accurately predicted the efficacy of IO and features of the TME in R/M HNSCC. Further study in a larger patient population is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Dan P Zandberg
Förderung
- NIH/NCI SPORE in Head and Neck Cancer
- NCI NIH HHS
- NIAID NIH HHS
- NIDCR NIH HHS
- The University of Pittsburgh Hillman Cancer Center startup funding (RRC)
- University of Pittsburgh Hillman Cancer Center NCI Cancer Center Support Grant (CCSG) (RRC)
Zitieren
APA
Zandberg, D. P., Zenkin, S., Ak, M., Mamindla, P., Peddagangireddy, V., Hsieh, R., Anderson, J. L., Delgoffe, G. M., Menk, A., Skinner, H. D., Duvvuri, U., Ferris, R. L., & Colen, R. R. (2025). Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐ PD ‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients. Head & Neck. https://doi.org/10.1002/hed.27878
Vancouver
Zandberg DP, Zenkin S, Ak M, Mamindla P, Peddagangireddy V, Hsieh R, et al. Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐ PD ‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients. Head & Neck. 2025. doi:10.1002/hed.27878
BibTeX
@article{Zandberg2025,
author = {Zandberg, Dan P and Zenkin, Serafettin and Ak, Murat and Mamindla, Priyadarshini and Peddagangireddy, Vishal and Hsieh, Ronan and Anderson, Jennifer L and Delgoffe, Greg M and Menk, Ashely and Skinner, Heath D and Duvvuri, Umamaheswar and Ferris, Robert L and Colen, Rivka R},
title = {Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐ PD ‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.27878}
}
EUVIMED